Factors associated with the occurrence of AIDS-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: Aquitaine Cohort, France

Clinical Infectious Diseases

Volumn 42, Issue 3, 2006, Pages 411-417

  Bonnet, Fabrice ^a,d   Balestre, Eric ^d   Thiébaut, Rodolphe ^d   Morlat, Philippe ^a,d   Pellegrin, Jean Luc ^b   Neau, Didier ^c   Dabis, François ^d  

^a HÔPITAL SAINT ANDRÉ   (France)

^b HAUT LÉVÊQUE HOSPITAL   (France)

^c HÔPITAL PELLEGRIN   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CIDOFOVIR; FOSCARNET; GANCICLOVIR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DRUG USE; FEMALE; FOLLOW UP; FRANCE; HERPES SIMPLEX; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FRANCE; HIV-1; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; RNA, VIRAL; SARCOMA, KAPOSI;

EID: 31044447107     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/499054     Document Type: Article

References (33)

1. Newton R, Ziegler J, Beral V, et al. A case-control study of human immunodeficiency virus infection and cancer in adults and children residing in Kampala, Uganda. Int J Cancer 2001; 92:622-7.
2. Beral V, Peterman T, Berkelman R, Jaffe H. AIDS-associated non-Hodgkin lymphoma. Lancet 1991; 337:805-9.
3. Centers for Disease Control and Prevention. Revision of the case definition of acquired immunodeficiency syndrome for national reporting. MMWR Morb Mortal Wkly Rep 1985; 34:373-5.
4. Grulich AE, Li Y, McDonald AM, Correll PK, Law MG, Kaldor JM. Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy. AIDS 2001; 15:629-33.
5. Matthews GV, Bower M, Mandalia S, Powles T, Nelson MR, Gazzard BG. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 2000; 96:2730-4.
6. Besson C, Goubar A, Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001; 98:2339-44.
7. Thiessard F, Morlat P, Marimoutou C, et al. Prognostic factors after non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus: Aquitaine Cohort, France, 1986-1997. Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA). Cancer 2000; 88:1696-702.
8. Levine AM, Seneviratne L, Espina BM, et al. Evolving characteristics of AIDS-related lymphoma. Blood 2000; 96:4084-90.
9. Gérard L, Galicier L, Maillard A, et al. Systemic non-Hodgkin lymphoma in HIV-infected patients with effective suppression of HIV replication: persistence occurrence but improved survival. J AIDS 2002; 30:478-84.
10. Bonnet F, Morlat P, Chene G, et al. Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999. HIV Med 2002; 3:195-9.
11. Bonnet F, Lewden C, May T, et al. Malignancies-related causes of death at the era of HAART: The French survey Mortalité 2000. Cancer 2004; 101:317-24.
12. Kirk O, Pedersen C, Cozzi-Lepri A, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001; 98:3406-12.
13. Grulich AE, Wan X, Law MG, et al. B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS. AIDS 2000; 14:133-40.
14. Piriou E, van Dort K, Nanlohy NM, et al. Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin Lymphoma. Blood 2005; 106:3166-74.
15. Mele A, Pulsoni A, Bianco E, et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood 2003; 102:996-9.
16. Iscovich I, Boffetta P, Franceschi S, Azizi E, Sarid R. Classic Kaposi sarcoma: epidemiology and risk factors. Cancer 2000; 88:500-17.
17. Marimoutou C, Chene G, Dabis F, Lacoste D, Salamon R. Human immunodeficiency virus infection and AIDS in Aquitaine: 10 years experience of a hospital information system, 1985-1995 [in French]. Le Groupe d'Epidemiologie Clinique du SIDA en Aquitaine. Presse Med 1997; 26:703-10.
18. Levine AM. Acquired immunodeficiency syndrome-related lymphoma: clinical aspects. Semin Oncol 2000; 27:442-53.
19. Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 2000; 356:291-6.
20. Systemic non-Hodgkin lymphoma in individuals with known dates of HIV seroconversion: incidence and predictors. CASCADE Collaboration. AIDS 2004; 18:673-81.
21. Pluda JM, Venzon DJ, Tosato G, et al. Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. J Clin Oncol 1993; 11:1099-107.
22. Cozzi Lepri A, Phillips AN, D'Arminio Monforte A, et al. When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study. AIDS 2001; 15:983-90.
23. Phillips AN, Staszewski S, Weber R, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 2001; 286:2560-7.
24. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286:2568-77.
25. Zuckerman E, Zuckerman T, Levine AM, et al. Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. Ann Intern Med 1997; 127:423-8.
26. Levine AM, Nelson R, Zuckerman E, et al. Lack of association between hepatitis C infection and development of AIDS-related lymphoma. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:255-8.
27. Subar M, Neri A, Inghirami G, Knowles DM, Dalla-Favera R. Frequent C-myc oncogene activation and infrequent presence of Epstein-Barr virus genome in AIDS-associated lymphoma. Blood 1988; 72:667-71.
28. Kaplan LD, Abrams DI, Feigal E, et al. AIDS-associated non-Hodgkin's lymphoma in San Francisco. JAMA 1989; 261:719-24.
29. Hansen PB, Penkowa M, Kirk O, et al. Human immunodeficiency virus-associated malignant lymphoma in eastern Denmark diagnosed from 1990-1996: clinical features, histopathology, and association with Epstein-Barr virus and human herpesvirus-8. Eur J Haematol 2000; 64:368-75.
30. Lin JC, Smith MC, Pagano JS. Comparative efficacy and selectivity of some nucleoside analogues against Apstein-Barr virus. Antimicrob Agents Chemother 1985; 27:971-3.
31. Malouf MA, Chhajed PN, Hopkins P, Plit M, Turner J, Glanville AR. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. J Heart Lung Transplant 2002; 21:547-54.
32. Darenkov IA, Marcarelli MA, Basadonna GP, et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 1997; 64:848-52.
33. Fong IW, Ho J, Toy C, Lo B, Fong MW. Value of long-term administration of acyclovir and similar agents for protecting against AIDS-related lymphoma: case-control and historical cohort studies. Clin Infect Dis 2000; 30:757-61.